Apyx Medical(APYX)

Focus: Apyx Medical is a publicly traded medical device company specializing in plasma-based aesthetic and body contouring technologies, with ~$48M in annual revenue and 501-1000 employees.

Unknown

Profile data last refreshed 17h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Employees

501-1000

Open Jobs

About Apyx Medical

AI assessmentNot Hiring

No open roles listed right now. Follow Apyx Medical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$48M

FY2025

Pipeline & Clinical Trials

Renuvion

Skin Laxity

N/A

Clinical Trials (5)

NCT05968495Measuring Renuvion Soft Tissue Contraction Using Ultrasound

N/A

Help build intelligence for Apyx Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Publicly traded company with recent FDA clearances (May 2026 AYON System expansion) demonstrating active regulatory momentum and product validation.
Focused niche market (aesthetic/cosmetic devices) with lower competition intensity than broad-spectrum pharma, offering clearer visibility into market drivers.
Recent 52-week stock high ($4.65 in June 2026) suggests investor confidence and potential upside for early-stage career moves.

Watch Out For

Declining revenue ($52M→$48M, -8% YoY) and persistent operating losses ($-18.7M→$-23.5M) indicate business headwinds despite product approvals.
Cash burn trajectory ($44M→$32M cash, -27% in 1 year) at current run-rate suggests 12-18 month runway; restructuring or acquisition risk is material.
Minimal hiring activity (0 active job openings) and low R&D spend ($5M, 11% intensity) signal limited career advancement and specialized/niche skill growth.

Generated by Claude from Apyx Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

NCT04146467Renuvion APR Device to Improve the Appearance of Lax Tissue in the Neck and Submental Region

N/A

NCT06243744Histological Evaluation of Human Skin Bx to Assess the Effects of APR Tx as an Adjunct Procedure in Facelift Surgery

N/A

J-Plasma

Facial Wrinkles

N/A

Clinical Trials (2)

NCT02658851Cold Plasma for the Reduction of Lymphoceles Following PLND

N/A

NCT03286283The Use of J-Plasma® for Dermal Resurfacing

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2011

Portfolio: 10 clinical trials

Publications: 25 in PubMed

SEC Filings: 2 available

Financials (FY2025)

Revenue

$48M8%

R&D Spend

$5M(11%)7%

Net Income

-$23M

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Biomedical application of cold plasma: navigating through plasma types and devices by antimicrobial effectiveness and tissue tolerance.

Advanced therapeutics

2025

PMID:40964152

Reply to Comment to: A Three-Dimensional Approach to Male Chest Enhancement: A Surgical Algorithm Based on 300 Cases.

Aesthetic plastic surgery

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo